Celltrion, Inc. Share Price Korea S.E.
Equities
068270
KR7068270008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- KRW | - |
01/07 | S.Korean shares rise on robust data; battery, biopharma stocks jump | RE |
17/06 | Celltrion Reveals Positive Phase III Results of Rheumatoid Arthritis Drug | MT |
Sales 2024 * | 3,436B 2.49B 208B | Sales 2025 * | 4,126B 2.99B 249B | Capitalization | 37,887B 27.43B 2,288B |
---|---|---|---|---|---|
Net income 2024 * | 524B 379M 31.65B | Net income 2025 * | 1,088B 788M 65.72B | EV / Sales 2024 * | 11.2 x |
Net Debt 2024 * | 755B 547M 45.63B | Net cash position 2025 * | 106B 76.77M 6.41B | EV / Sales 2025 * | 9.16 x |
P/E ratio 2024 * |
74.8
x | P/E ratio 2025 * |
35.8
x | Employees | - |
Yield 2024 * |
0.24% | Yield 2025 * |
0.26% | Free-Float | 66.89% |
Managers | Title | Age | Since |
---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 24/07/24 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 49 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Soon-Woo Lee
BRD | Director/Board Member | 73 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jong-Seok Lee
BRD | Director/Board Member | 72 | 08/14/08 |
1st Jan change | Capi. | |
---|---|---|
+16.59% | 45.51B | |
-9.89% | 38.52B | |
+38.08% | 38.13B | |
+27.12% | 30.74B | |
+11.81% | 25.92B | |
+45.08% | 14.13B | |
+32.85% | 12.73B | |
-7.19% | 11.29B | |
-14.03% | 10.64B |
- Stock Market
- Equities
- A068270 Stock
- 068270 Stock